
Signos is on a mission to tackle the obesity epidemic via healthy habits, glucose level stabilization, and AI. Signos combines continuous glucose information with an AI-enhanced app to offer revolutionary continuous data and recommendations designed to drive healthy and sustained weight loss. With over 75% of the American population overweight or obese, Signos provides a new way for people to act on their body’s unique response to what they eat to lose weight and kickstart a healthier life

Signos is on a mission to tackle the obesity epidemic via healthy habits, glucose level stabilization, and AI. Signos combines continuous glucose information with an AI-enhanced app to offer revolutionary continuous data and recommendations designed to drive healthy and sustained weight loss. With over 75% of the American population overweight or obese, Signos provides a new way for people to act on their body’s unique response to what they eat to lose weight and kickstart a healthier life
What they do: Metabolic health and weight-loss program combining continuous glucose monitors (CGMs) with an AI-enhanced mobile app
Founded / HQ: 2018; Burlingame, California
Funding: Total ≈ $37M — Series B $20M (Oct 2023)
Employees: 104
Availability / Coverage: Available across the United States; does not accept insurance
Obesity and metabolic health / weight management
2018
Metabolic health / weight loss
4,000,000 USD
Angel investors disclosed include Larry Fitzgerald, Kelvin Beachum, and Jerod Mayo (per company disclosures)
13,000,000 USD
20,000,000 USD
Additional participation from Dexcom Ventures and Samsung Next
“Venture-backed with participation from GV (Google), Dexcom Ventures, and Samsung Next; Series B led by Cheyenne Ventures and GV”